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Urocanic acid (UCA) is present at millimolar concentrations in mammalian epidermis and undergoes photo-
isomerization from the naturally occurring trans-isomer to the cis-isomer on exposure to ultraviolet radiation
(UVR). Cis-UCA causes downregulation of various immune responses in mouse and human experimental models
and has been proposed as both a chromophore and a mediator of UV-induced immune suppression. In this study,
the wavelength dependence from 260–340 nm for trans to cis-UCA photoisomerization in human skin was analyzed
in ﬁve healthy volunteers. The resulting action spectrum demonstrated maximal cis-UCA production in the UVB
spectral region of 280–310 nm. This spectral peak is red-shifted to longer wavelengths compared with the ery-
themal action spectrum. The cis-UCA action spectrum can be used to predict the ability of sunscreens to protect
against UVR-induced cis-UCA formation and may assist in explaining discrepancies between sunscreens’ abilities
to protect against erythema and photoimmunosuppression.
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Ultraviolet radiation (UVR) exposure of human and rodent
skin suppresses cell-mediated immune responses (Fisher
and Kripke, 1977; Schwarz, 2002). This photoimmunosup-
pression decreases resistance to tumor cells and microbial
infections (Duthie et al, 1999). The skin chromophores re-
sponsible for initiating photoimmunosuppression are not
fully defined but there is considerable evidence that DNA
(Vink et al, 1996; Nghiem et al, 2002) and urocanic acid
(UCA; (2-propanoic acid, 3-[imidazol-4 (5)-yl]) (Kim et al,
2003) are candidates.
UCA is present as trans-UCA in the stratum corneum of
human skin in high (mM) concentrations (Kavanagh et al,
1995). On exposure to UVR, trans-UCA is photoisomerized
to cis-UCA (Edlbacher and Hertz, 1943). Photoisomerization
of trans-UCA increases in a UVR dose-dependent fashion
until a ‘‘photostationary’’ level is reached at approximately
60% cis-UCA. The original proposal that trans-UCA may be
the chromophore for photoimmunosuppression was made
by De Fabo and Noonan (1983) who demonstrated that the
UVR wavelength dependence (action spectrum) for sup-
pression of contact hypersensitivity (CHS) in mice peaked at
260–270 nm and was super-imposable on the absorption
spectrum of trans-UCA. When the trans-UCA-containing
stratum corneum was removed by tape stripping, the mice
became refractory to photoimmunosuppression (De Fabo
and Noonan, 1983). Subsequent studies have demonstrat-
ed that cis-UCA can suppress contact and delayed type
hypersensitivity, resistance to infectious diseases, skin and
other allograft rejection, and graft-versus-host disease in
rodents (Norval and El Ghorr, 2002). Cis-UCA also increases
the risk of non-melanoma skin cancer in mouse models
(Reeve et al, 1989; Beissert et al, 2001).
The immunosuppressive properties of UCA in human
subjects have not been studied in vivo but in vitro exper-
iments indicate that cis-UCA can suppress natural killer cell
activity (Gilmour et al, 1993), suppress antigen presenting
function (Hurks et al, 1997), stimulate PGE2 production by
mononuclear cells (Hart et al, 1993) and keratinocytes (Jak-
sic et al, 1995), and suppress HLA-DR, IL-1b, IL-2, TNFa,
and IL-1b production by mononuclear cells (Rasanen et al,
1989; Hart et al, 1993; Laihia et al, 1994).
In vivo, the critical event is the production of immuno-
suppressive cis-UCA from trans-UCA by photoisomerizat-
ion. At a particular wavelength, the yield of cis-UCA is
dependent on absorption by trans-UCA (peak absorption at
 270 nm) and the quantum yield for the photoisomerizat-
ion reaction. As work by Morrison et al (1984) had demon-
strated that the quantum yields for trans- to cis-UCA
photoisomerization in vitro are wavelength dependent, there
was a high probability that the action spectrum (wavelength
dependence) for the reaction would not match the absorp-
tion spectrum of trans-UCA. Gibbs et al (1993) confirmed
this hypothesis by producing an action spectrum for trans-
to cis-UCA photoisomerization in mouse skin in vivo which
peaked at 310–315 nm rather than at the trans-UCA ab-
sorption maximum of  270 nm.
Despite the potential importance of cis-UCA as a natural
immunosuppressant, the action spectrum for its production
in human skin is not known. Kammeyer et al (1995) as-
sessed UCA photoisomerization in three healthy subjects
using filters to produce nine ‘‘narrow’’ (mean of  33 nm)
wavebands of UVR over the range of 295–405 nm. Three
UVR doses were given at each waveband, which had beenAbbreviations: UCA, urocanic acid; UVR, ultraviolet radiation
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weighted for erythemal effectiveness and solar irradiance.
At the higher doses used in the 305 and 326 nm band-
widths, the photostationary state was approached which
makes interpretation of the resultant, weighted spectrum
difficult. In order to accurately define the wavelength de-
pendence for the formation of cis-UCA in human skin we
have conducted a full action spectrum over the wavelength
region of 260–340 nm in five healthy volunteers. We dem-
onstrate how data from this action spectrum can be used to
predict the ability of sunscreens to protect against UVR-
induced cis-UCA formation and may assist in explaining
discrepancies between sunscreens’ abilities to protect
against erythema and photoimmunosuppression.
Results
Figure 1 shows the percentage of cis-UCA extracted from
all subjects, at each dose and waveband (260–340 nm)
studied together with the mean slope (  standard error)
calculated using a random effects model. These slopes
were plotted against wavelength to give an action spectrum
(Fig 2) which is shown together with the CIE erythemal ac-
tion spectrum (CIE; McKinlay and Diffey, 1987).
Discussion
In this study, we present the action spectrum for the pro-
duction of cis-UCA in human skin. Both the human and
mouse (Gibbs et al, 1993) spectra peak at longer wave-
lengths than the absorption spectrum of trans-UCA (peak
absorption at  270 nm). In many photochemical reac-
tions, the absorption spectrum of the chromophore is a
reliable predictor of the action spectrum for the photo-
biological event (e.g., chlorophyll and photosynthesis). This
relationship, however, relies on the (normally valid) assump-
tion that the quantum yield is constant across all wave-
bands. This assumption does not hold in the case of UCA;
due to complex reactions of the the trans-UCA singlet state,
the quantum yield for trans- to cis-UCA photoisomerization
(Ft ! c) in vitro is 0.49 at 310 nm but only 0.08 at 280 nm
(Morrison et al, 1984; Hanson and Simon, 1998). The in-
creased Ft ! c at longer wavelengths results in a red-shift-
ing of the action spectra peaks to wavelengths longer than
the peak absorption of trans-UCA.
The action spectrum can be used to examine the ability
of sunscreens to protect against UVR-induced cis-UCA
production. Van der Molen et al (2000) used two sunscreen
preparations (T10, absorbing both UVB and UVA and B10,
primarily absorbing UVB) with equal sun protection factors
(SPF) against erythema of 10. The sunscreens were applied
to dorsal skin and their ability to protect against broad-band
UVR (Philips TL-12 Philips, Guildford, UK)-induced cis-UCA
production was assessed. From the published sunscreen
absorption spectra (Fig 6 in van der Molen et al, 2000) it is
possible to calculate the transmittance (T(l)) of the two
sunscreens at wavelength l. These values are then convo-
luted with the relative spectral output (E(l)) of the TL-12
source and U(l), the efficiency of cis-UCA production from
Fig 2 to predict the relative cis-UCA produced (cis) by TL-12
irradiation through each of the sunscreens.
cis ¼
Z 340
260
EðlÞTðlÞUðlÞdl
From the above equation the protective factors against cis-
UCA production for the T10 and B10 sunscreens are cal-
culated as 4.4 and 1.9, respectively. The finding that the T10
sunscreen is more efficient at protecting against TL-12 in-
duced cis-UCA production agrees favorably with the em-
pirical in vivo data presented by van der Molen et al (2000).
These calculations emphasize that sunscreens with equal
SPF will not necessarily have equal abilities to protect
against cis-UCA production and perhaps suggests that they
will also not protect equally against photoimmunosuppres-
sion. The implication is that the action spectra for erythema
and photoimmunosuppression are different. This is support-
ed by several studies in humans, conducted on both the
sensitization and elicitation phases of CHS, demonstrating
that sunscreens protecting against erythema (predominately
UVB absorbers) do not show as good protection against
photoimmunosuppression as broad spectrum sunscreens
(UVB and UVA absorbers) (Fourtanier et al, 2000; Baron et al,
2003; Poon et al, 2003). From Fig 2 it is clear that the cis-
UCA action spectrum is red-shifted compared with the CIE
erythema spectrum and this suggests that sunscreens that
primarily absorb erythemogenic radiation may fail to prevent
cis-UCA formation. In contrast, broad-spectrum sunscreens
will be efficient at protecting against both erythema and cis-
UCA formation. Whilst further studies are required to clarify
the role of cis-UCA in human photoimmunosuppression, it is
tempting to speculate that a failure to protect against cis-
UCA production is linked to the demonstrated failure of
some sunscreens to protect against immunosuppression.
Materials and Methods
Subjects Five healthy Caucasian volunteers, (26–37 y), three
males, skin types I–III, were enrolled in this local ethics commit-
tee approved study after giving informed consent in accordance
with Declaration of Helsinki Principles. They were not taking sys-
temic medication and had not exposed their dorsal skin to solar or
artificial UVR for 3 mo prior to the study.
Monochromator A single grating monochromator (Rank Hilger
D330 Rank Hilger, Margate, UK) with a 450 W xenon arc source
was used (Gibbs et al, 1993). The output was directed via a 5 mm
diameter liquid light guide (Oriel Corporation, Leatherhead, UK).
At wavebands 330 and 340 nm a Schott WG305 cut-off filter
was used. Wavelength and bandwidth (half-maximal bandwidth
 2.6 nm) calibrations were conducted using a Bentham double-
grating spectroradiometer (Bentham Instruments, Reading, UK).
Irradiance was measured with a calibrated Hilger Watts 2M8 ther-
mopile (both thermopile and spectroradiometer calibrations were
traceable to the National Physical Laboratory, Teddington, UK).
Skin irradiation All irradiations were conducted in the UK winter
months from November to February. Strips of double-sided adhe-
sive tape with 9  5-mm diameter apertures were placed across
the dorsal skin region of each subject. The skin within each ap-
erture was irradiated using the liquid light guide with narrow wave-
bands centered at 260, 270, 280, 290, 300, 315, 320, 330, and 340
nm (half-maximal band width ¼ 2.6 nm). Doses were administered
at 0–30 mJ per cm2 in 5 mJ per cm2 increments for wavebands
260–320 nm and 0–60 mJ per cm2 at 10 mJ per cm2 increments for
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wavebands 330 and 340 nm. At each waveband there were also
triplicate non-irradiated sites.
UCA extraction procedure (modiﬁed from Jansen et al, 1991) Im-
mediately after irradiation, 5 mm diameter filter paper discs were in-
serted in each punched hole of the double-sided tape. To extract the
UCA from the skin 5 mL of 0.1 M KOH were pipetted on to each disc
and the area was occluded for 1 h with a polythene cover stuck on the
upper adhesive side of the double side tape. The discs were subse-
quently placed in individual eppendorf tubes containing 195 mL of 0.1
M KOH, vortexed and stored at 201C for up to 5 d before analysis.
HPLC analysis Standard curves of pure trans-UCA (Sigma
Aldrich, Poole, UK) and chromatographically purified cis-UCA
(Norval et al, 1988) were constructed at concentrations of 6.25 ng
to 0.4 mg per 50 mL mobile phase buffer. HPLC was carried out as
described previously (Gibbs et al, 1993) but using a mobile phase
flow rate of 1 mL per min. Individual peaks were observed for
Figure 1
Wavelength dependent production of cis-
urocanic acid in human skin in vivo.
Subjects’ (n¼5) dorsal skin was irradiated
with increasing doses of wavebands (  2.6
nm) centered at 260, 270, 280, 290, 300,
310, 315, 320, 330, and 340 nm. Plotted
mean regressions were fitted using a ran-
dom effects model.
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cis- and trans-UCA, eluting after approximately 6 and 8 min,
respectively.
Calculation of cis-UCA production rate; statistical analysis At
each waveband, cis-UCA levels from each subject were quantified
as a percentage of total UCA (transþ cis) extracted and plotted
against UV dose. The slopes of the five subjects were calculated
by regression analysis and averaged using a random effects model
to allow for heterogeneity between individuals. The resultant mean
slope (  standard error) was used as a measurement of the cis-
UCA production rate (% cis-UCA per mJ per cm2) and plotted
against wavelength to give an action spectrum.
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Figure 2
An action spectrum for cis-urocanic acid production in human skin
in vivo. The action spectrum for cis-urocanic acid production (solid line)
is plotted with vertical bars depicting the standard errors of fitted linear
slopes shown in Fig 1. The cis-urocanic and spectrum is noticeably red-
shifted compared to the CIE erythema action spectrum (dashed line).
1074 McLOONE ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
